Recurrent ovarian cancer.
J
J
Pfisterer
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D019233:Retreatment; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects; D017211:Treatment Failure; D000093542:Gemcitabine
D003841:Deoxycytidine; D019772:Topotecan; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine